Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current management of tuberculosis.

N J Snell1

  • 1Bayer Pharma, Stoke Court, Stoke Poges, Slough, SL2 4LY, UK.

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Current tuberculosis treatments are effective but limited by few new drugs and rising drug resistance. Factors like HIV, aging, poverty, and conflict are reversing global declines in tuberculosis cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The treatment of tuberculosis: current status and future prospects.

Expert opinion on investigational drugs·2005
Same author

Ribavirin--current status of a broad spectrum antiviral agent.

Expert opinion on pharmacotherapy·2001
Same author

Emerging infectious diseases--a therapeutic challenge.

Expert opinion on pharmacotherapy·2001
Same author

New treatments for viral respiratory tract infections--opportunities and problems.

The Journal of antimicrobial chemotherapy·2001
Same author

Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998.

Respiratory medicine·1999
Same author

New developments in the treatment of viral respiratory tract infections.

Expert opinion on investigational drugs·1997
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Medicine
  • Infectious Diseases
  • Public Health

Background:

  • Current tuberculosis (TB) chemotherapy offers high cure and low relapse rates when properly managed.
  • Limited development of new anti-TB drugs over the past 30 years poses a challenge.
  • Suboptimal management and patient non-compliance contribute to the rise of drug-resistant TB strains.

Purpose of the Study:

  • To highlight the effectiveness of current TB chemotherapy.
  • To underscore the challenges posed by limited new drug development.
  • To identify factors contributing to the increasing prevalence of drug-resistant tuberculosis.

Main Methods:

  • Review of current chemotherapeutic regimens for tuberculosis.
  • Analysis of factors influencing treatment outcomes and relapse rates.

Related Experiment Videos

  • Examination of the impact of patient compliance and management on drug resistance.
  • Assessment of epidemiological trends and contributing factors to TB resurgence.

    • Main Results:

    • Effective cure and low relapse rates are achievable with current TB chemotherapy under ideal conditions.
    • The scarcity of new anti-TB drugs approved in the last three decades is a significant concern.
    • Increasing prevalence of drug-resistant organisms is linked to management deficiencies and poor patient adherence.
    • Global TB decline has been reversed due to the HIV epidemic, aging populations, poverty, and population displacement.

    Conclusions:

    • While current TB treatments can be highly effective, their success is contingent on proper implementation and patient compliance.
    • The emergence and spread of drug-resistant tuberculosis are exacerbated by systemic issues in healthcare management and patient adherence.
    • A confluence of public health crises, including HIV/AIDS, demographic shifts, socioeconomic factors, and conflict-driven migration, is driving a resurgence of tuberculosis globally.